02 Jun 2015
Quantum Pharma Plc. a service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has been informed today that LDC (Managers) Limited, acting as investment manager on behalf of Lloyds Development Capital (Holdings) Limited, OBS 2009 LP and LDC Opportunity Club 2009, has sold an aggregate of 8,800,000 ordinary shares today representing c.7.04 per cent. of the total number of voting rights in the Group (the “Transaction”). Zeus Capital has given its consent to release these shares from the lock-in agreed at the time of the Group’s Admission to AIM due to the high level of institutional demand for Quantum’s shares following the Group’s recent annual results announcement. The ordinary shares have been successfully placed today by Zeus Capital to a small number of existing shareholders.
Following the Transaction, the funds managed by LDC continue to hold a non-discloseable interest in the ordinary shares and the total voting rights in Quantum. These shares remain subject to a lock-in which expires on 11 June 2015.
Andrew Scaife, CEO of Quantum Pharma, commented: “Following strong demand from institutional investors at the time of the Group’s final results roadshow in late May, we are pleased that, working in conjunction with our broker, we have been able to successfully satisfy this demand through the desire of LDC to reduce their holding to below 3%.
“LDC have played a pivotal role in the development of the Group since the MBO in 2009 and the Board joins me in thanking them for their support over the last six years. We welcome our new shareholders as we continue to make solid progress with our strategy as a quoted company.”